{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:08:00Z","timestamp":1759018080467,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.jinf.2005.09.007","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:37:29Z","timestamp":1131007049000},"page":"36-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pegylated interferon \u03b1-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients"],"prefix":"10.1016","volume":"53","author":[{"given":"Esther","family":"Voigt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Klausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Goelz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Mauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenther","family":"Schmutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutwin","family":"Weitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonius","family":"Mutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Schranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"for the KAAD study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2005.09.007_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01719475","article-title":"Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positve patients","volume":"11","author":"Francisci","year":"1995","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jinf.2005.09.007_bib2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1128\/CDLI.8.5.867-870.2001","article-title":"Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infection","volume":"8","author":"Nelson","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jinf.2005.09.007_bib3","unstructured":"Rockstroh J, Konopnicki D, Soriano V, Kirk O, Anfunes F, Knysz R, et al. Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART. 11th. 2004 799"},{"key":"10.1016\/j.jinf.2005.09.007_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"del Olmo","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.jinf.2005.09.007_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc group","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2005.09.007_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9270(00)02167-5","article-title":"Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C","volume":"96","author":"Garcia-Samaniego","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jinf.2005.09.007_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/380130","article-title":"Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a european collaborative study","volume":"38","author":"Martin-Carbonero","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2005.09.007_bib8","first-page":"2563","article-title":"Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV","volume":"91","author":"Rockstroh","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jinf.2005.09.007_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1097\/00002030-200308150-00009","article-title":"Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)","volume":"17","author":"Rosenthal","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2005.09.007_bib10","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1097\/00002030-200210180-00016","article-title":"Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients","volume":"16","author":"Rockstroh","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2005.09.007_bib11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00002030-200111090-00010","article-title":"Long-term efficacy of combination therapy with interferon-\u03b12b and ribavirin for severe chronic hepatitis C in HIV-infected patients","volume":"15","author":"Landau","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2005.09.007_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/clinids\/23.3.585","article-title":"Interferon \u03b1 for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus","volume":"23","author":"Soriano","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2005.09.007_bib13","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2005.09.007_bib14","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2005.09.007_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2005.09.007_bib16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2005.09.007_bib17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated IFN-\u03b12b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"Perez-Olmeda","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2005.09.007_bib18","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa 2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2005.09.007_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002030-200401020-00008","article-title":"Pegylated interferon \u03b12b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients","volume":"18","author":"Moreno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2005.09.007_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2005.09.007_bib21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2005.09.007_bib22","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2005.09.007_bib23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-\u03b12a and ribavirin combination therapy in chronic hepatitis C","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jinf.2005.09.007_bib24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/088922204323048096","article-title":"Hepatitis C Virus relapses after anti-HCV therapy are more frequent in HIV-infected patients","volume":"20","author":"Soriano","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jinf.2005.09.007_bib25","unstructured":"Moreno L, Quereda C, Moreno A, Perez Ehas MJ, Casab JL, Antela A, et al. Outcome and safety of IFN\/RBV in HCV\/HIV coinfected patients with advanced fibrosis. 44th ICAAC Washington DC, USA, October 30th\u2013November2nd 2004, Abstract V-784."},{"issue":"13","key":"10.1016\/j.jinf.2005.09.007_bib26","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in cirrhotic patients with HIV\/HCV coinfection and liver cirrhosis during interferon based therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445305002859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445305002859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:29:54Z","timestamp":1758986994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445305002859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0163445305002859"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2005.09.007","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegylated interferon \u03b1-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2005.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}